Studies have confirmed that the combination of imatinib mesylate and PI3K inhibitors in the treatment of GIST xenograft models was more effective, with a more durable response compared to the use of a single-agent [134,137,138]. Here, PIK3CA is linked to gastrointestinal stromal tumor.